HER2-targeted antibody drug conjugate shows strong anti-tumor activity and durable responses across multiple tumors (Many forms of cancer)

Medical Xpress / Univ of Texas M. D. Anderson / American Society of Clinical Oncology ^ | June 5, 2023 | Funda Meric-Bernstam, M.D. et al

[ConservativeMind]

In a new study of trastuzumab deruxtecan, a HER2-targeted antibody drug conjugate, researchers observed encouraging responses and long-lasting clinical benefit in several tumor types. These data from an interim analysis of the Phase II DESTINY-PanTumor02 study.

The treatment achieved an objective response rate (ORR) of 61.3% with a median duration of response (DOR) of 22.1 months in patients with the highest levels of HER2 expression. Across all patients, the ORR was 37.1% with a median DOR of 11.8 months. An ORR of more than 30% was observed in all cancer types except biliary tract (22%) and pancreatic cancers (4%).

Antibody drug conjugates work by utilizing an antibody to target and bind to a specific protein, in this case HER2, and delivering chemotherapy directly to the cell. Trastuzumab deruxtecan is approved for HER2-expressing breast cancer, gastric cancer and lung cancer. However, HER2 also is expressed in several other tumor types.

This international open-label study was designed to evaluate the anti-tumor activity of trastuzumab deruxtecan in patients with HER2-expressing locally advanced or metastatic cancers. The trial included 267 patients with cervical, endometrial, ovarian, biliary tract, pancreatic and bladder cancers, as well as other tumors.

The level of HER2 expression was measured by an immunohistochemistry (IHC) test. Seventy-five patients scored IHC 3+, indicating the highest level of HER2 expression, and 125 scored IHC 2+ by central testing. Most patients were female (67%) with an average age of 62 years and a median of two prior lines of therapy.

Meric-Bernstam said: "This could help provide a new treatment option for these patients with advanced disease and hard-to-treat HER2-positive cancers who currently have very limited or no options."

This trial is ongoing, with several patients still receiving treatment. The progression-free survival and overall survival will be analyzed with further follow-up.

[ConservativeMind]

This helped people with many cancers, “…cervical, endometrial, ovarian, biliary tract, pancreatic and bladder cancers, as well as other tumors.”

Trastuzumab deruxtecan is available today.

[ConservativeMind]

The “Take Charge Of Your Health” Ping List
This high volume ping list is for health articles and studies which describe something you or your doctor, when informed, may be able to immediately implement for your benefit.

Email me to get on either the “Common/Top Issues” (20 - 25% fewer pings) or “Everything” list.

[ClearCase_guy]

The name is politically incorrect and should be adjusted to THEM2.

[PMAS]

******